ERBB2 and neoplasm: As biomarkers, the RAS gene, BRAF gene, and dMMR (mismatch repair deficient)/MSI-H (microsatellite instability-high), TMB-H (tumor mutation burden-high), and HER2 statuses have been evaluated in clinical practice, and the corresponding molecularly targeted therapeutic agents should be selected based on the biomarker status.